{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:26:34Z","timestamp":1788531994446,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01684-8","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:59:19Z","timestamp":1788530359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors"],"prefix":"10.1007","author":[{"given":"Zaid N. Al","family":"Shirity","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Dontje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs H. Oude","family":"Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn N. Lub-de","family":"Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahez","family":"Gareb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-020-00977-0","volume":"13","author":"L Huang","year":"2020","unstructured":"Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20\u00a0years (2001\u20132020). J Hematol Oncol. 2020;13:1\u201323. https:\/\/doi.org\/10.1186\/S13045-020-00977-0.","journal-title":"J Hematol Oncol"},{"key":"1684_CR2","doi-asserted-by":"publisher","unstructured":"Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, et al. Receptor tyrosine kinase inhibitors in cancer. 2023;80:104. https:\/\/doi.org\/10.1007\/s00018-023-04729-4.","DOI":"10.1007\/s00018-023-04729-4"},{"key":"1684_CR3","doi-asserted-by":"publisher","unstructured":"Sunder SS, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. https:\/\/doi.org\/10.1038\/s41392-023-01469-6","DOI":"10.1038\/s41392-023-01469-6"},{"key":"1684_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.00177","author":"T Buclin","year":"2020","unstructured":"Buclin T, Thoma Y, Widmer N, Andr\u00e9 P, Guidi M, Csajka C, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/FPHAR.2020.00177.","journal-title":"Front Pharmacol"},{"key":"1684_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/S12943-018-0801-5","author":"Q Jiao","year":"2018","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018. https:\/\/doi.org\/10.1186\/S12943-018-0801-5.","journal-title":"Mol Cancer"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/J.CTRV.2010.08.006","volume":"37","author":"HJ Kl\u00fcmpen","year":"2011","unstructured":"Kl\u00fcmpen HJ, Samer CF, Mathijssen RHJ, Schellens JHM, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37:251\u201360. https:\/\/doi.org\/10.1016\/J.CTRV.2010.08.006.","journal-title":"Cancer Treat Rev"},{"key":"1684_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.821807","volume":"12","author":"N Verougstraete","year":"2022","unstructured":"Verougstraete N, Stove V, Verstraete AG, Stove CP, Frontiers Media SA. Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples. Front Oncol. 2022;12:1. https:\/\/doi.org\/10.3389\/FONC.2022.821807.","journal-title":"Front Oncol"},{"key":"1684_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/S40262-023-01293-9","volume":"62","author":"MBA van der Kleij","year":"2023","unstructured":"van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, et al. Therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacokinet. 2023;62:1333. https:\/\/doi.org\/10.1007\/S40262-023-01293-9.","journal-title":"Clin Pharmacokinet"},{"key":"1684_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/KJIM.2009.24.1.1","volume":"24","author":"JS Kang","year":"2009","unstructured":"Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1\u201310. https:\/\/doi.org\/10.3904\/KJIM.2009.24.1.1.","journal-title":"Korean J Intern Med"},{"key":"1684_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14061216","author":"V Escudero-Ortiz","year":"2022","unstructured":"Escudero-Ortiz V, Dom\u00ednguez-Le\u00f1ero V, Catal\u00e1n-Latorre A, Rebollo-Liceaga J, Sureda M, Multidisciplinary Digital Publishing Institute (MDPI). Relevance of therapeutic drug monitoring of tyrosine kinase inhibitors in routine clinical practice: a pilot study. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14061216.","journal-title":"Pharmaceutics"},{"key":"1684_CR11","doi-asserted-by":"publisher","unstructured":"Goutelle S, Guidi M, Gotta V, Csajka C, Buclin T, Widmer N. From personalized to precision medicine in oncology: a model-based dosing approach to optimize achievement of imatinib target exposure. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15041081.","DOI":"10.3390\/pharmaceutics15041081"},{"key":"1684_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FTD.0000000000000771","volume":"42","author":"L Smy","year":"2020","unstructured":"Smy L, Sadler AJ, McMillin GA. Evaluation of imatinib concentrations in samples submitted for BCR-ABL1 or imatinib testing\u2014evidence to support therapeutic drug monitoring for dose optimization? Ther Drug Monit. 2020;42:559\u201364. https:\/\/doi.org\/10.1097\/FTD.0000000000000771.","journal-title":"Ther Drug Monit"},{"key":"1684_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/S40262-024-01399-8","volume":"63","author":"M Meertens","year":"2024","unstructured":"Meertens M, Giraud EL, van der Kleij MBA, Westerdijk K, Guchelaar NAD, Bleckman RF, et al. Evaluating the clinical impact and feasibility of therapeutic drug monitoring of pazopanib in a real-world soft-tissue sarcoma cohort. Clin Pharmacokinet. 2024;63:1045\u201354. https:\/\/doi.org\/10.1007\/S40262-024-01399-8.","journal-title":"Clin Pharmacokinet"},{"key":"1684_CR14","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/BCP.13327","volume":"83","author":"NAG Lankheet","year":"2017","unstructured":"Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017;83:2195\u2013204. https:\/\/doi.org\/10.1111\/BCP.13327.","journal-title":"Br J Clin Pharmacol"},{"key":"1684_CR15","unstructured":"Homepage | KNMP [Internet]. 2024. https:\/\/www.knmp.nl\/. Accessed 1 Dec 2024."},{"key":"1684_CR16","doi-asserted-by":"publisher","unstructured":"Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth; 2019;22:67. https:\/\/doi.org\/10.4103\/ACA.ACA_157_18.","DOI":"10.4103\/ACA.ACA_157_18"},{"key":"1684_CR17","doi-asserted-by":"publisher","unstructured":"Giraud EL, Westerdijk K, van der Kleij MBA, Guchelaar NAD, Meertens M, Bleckman RF, et al. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes. ESMO Open; 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103477.","DOI":"10.1016\/j.esmoop.2024.103477"},{"key":"1684_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","volume":"36","author":"NAG Lankheet","year":"2014","unstructured":"Lankheet NAG, Knapen LM, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit. 2014;36:326\u201334. https:\/\/doi.org\/10.1097\/FTD.0000000000000004.","journal-title":"Ther Drug Monit"},{"key":"1684_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/BCP.14332","volume":"87","author":"K Westerdijk","year":"2021","unstructured":"Westerdijk K, Krens SD, van der Graaf WTA, Mulder SF, van Herpen CML, Smilde T, et al. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. Br J Clin Pharmacol. 2021;87:326\u201335. https:\/\/doi.org\/10.1111\/BCP.14332.","journal-title":"Br J Clin Pharmacol"},{"key":"1684_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2020.05.025","volume":"136","author":"NS IJzerman","year":"2020","unstructured":"IJzerman NS, Groenland SL, Koenen AM, Kerst M, van der Graaf WTA, Rosing H, et al. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours\u2014results from daily clinical practice. Eur J Cancer. 2020;136:140\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2020.05.025.","journal-title":"Eur J Cancer"},{"key":"1684_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/S40262-016-0439-7","volume":"56","author":"S Farag","year":"2017","unstructured":"Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema ADR, Steeghs N. Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients. Clin Pharmacokinet. 2017;56:287\u201392. https:\/\/doi.org\/10.1007\/S40262-016-0439-7.","journal-title":"Clin Pharmacokinet"},{"key":"1684_CR22","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490\/85046\/AM\/a-long-term-prospective-population-pharmacokinetic","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK, De Jong FA, Sparreboom A, Van Der Graaf WTA, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Research. 2012;18:5780\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0490\/85046\/AM\/a-long-term-prospective-population-pharmacokinetic.","journal-title":"Clin Cancer Research"},{"key":"1684_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/J.EJCA.2015.12.029","volume":"57","author":"S Bouchet","year":"2016","unstructured":"Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer Pergamon. 2016;57:31\u20138. https:\/\/doi.org\/10.1016\/J.EJCA.2015.12.029.","journal-title":"Eur J Cancer. Pergamon"},{"key":"1684_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/FCP.12007;JOURNAL:JOURNAL:14728206;WGROUP:STRING:PUBLICATION","volume":"27","author":"S Bouchet","year":"2013","unstructured":"Bouchet S, Titier K, Moore N, Lassalle R, Ambrosino B, Poulette S, et al. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol. 2013;27:690\u20137. https:\/\/doi.org\/10.1111\/FCP.12007;JOURNAL:JOURNAL:14728206;WGROUP:STRING:PUBLICATION.","journal-title":"Fundam Clin Pharmacol"},{"key":"1684_CR25","doi-asserted-by":"publisher","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. 2008. https:\/\/doi.org\/10.1182\/blood-2007-10.","DOI":"10.1182\/blood-2007-10"},{"key":"1684_CR26","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/PHARMACEUTICS14081676\/S1","volume":"14","author":"H Johnson-Ansah","year":"2022","unstructured":"Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, et al. Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia. Pharmaceutics. 2022;14:1676. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14081676\/S1.","journal-title":"Pharmaceutics"},{"key":"1684_CR27","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/CPT.1989;JOURNAL:JOURNAL:15326535;WGROUP:STRING:PUBLICATION","volume":"109","author":"SL Groenland","year":"2021","unstructured":"Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, et al. Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small cell lung cancer patients. Clin Pharmacol Ther. 2021;109:394\u2013402. https:\/\/doi.org\/10.1002\/CPT.1989;JOURNAL:JOURNAL:15326535;WGROUP:STRING:PUBLICATION.","journal-title":"Clin Pharmacol Ther"},{"key":"1684_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz244","author":"SL Groenland","year":"2019","unstructured":"Groenland SL, Van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study 5. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz244.","journal-title":"Ann Oncol"},{"key":"1684_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/CPT.956","volume":"104","author":"Y Cleary","year":"2018","unstructured":"Cleary Y, Gertz M, Morcos PN, Yu L, Youdim K, Phipps A, et al. Model-based assessments of CYP-mediated drug-drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development. Clin Pharmacol Ther. 2018;104:505\u201314. https:\/\/doi.org\/10.1002\/CPT.956.","journal-title":"Clin Pharmacol Ther"},{"key":"1684_CR30","doi-asserted-by":"publisher","first-page":"1136221","DOI":"10.3389\/FONC.2023.1136221\/BIBTEX","volume":"13","author":"M Meertens","year":"2023","unstructured":"Meertens M, Muntinghe-Wagenaar MB, Sikkema BJ, Lopez-Yurda M, Ret\u00e8l VP, Paats MS, et al. Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC). Front Oncol. 2023;13:1136221. https:\/\/doi.org\/10.3389\/FONC.2023.1136221\/BIBTEX.","journal-title":"Front Oncol"},{"key":"1684_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/FTD.0000000000000639","volume":"41","author":"T Iwamoto","year":"2019","unstructured":"Iwamoto T, Monma F, Ohishi K, Umino A, Suzuki K, Oka K, et al. Evaluation of medication adherence and pharmacokinetics of dasatinib for earlier molecular response in Japanese patients with newly diagnosed chronic myeloid leukemia: a pilot study. Ther Drug Monit. 2019;41:575\u201381. https:\/\/doi.org\/10.1097\/FTD.0000000000000639.","journal-title":"Ther Drug Monit"},{"key":"1684_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/CPT.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102:765\u201376. https:\/\/doi.org\/10.1002\/CPT.787.","journal-title":"Clin Pharmacol Ther"},{"key":"1684_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/CPAA.S42796","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol. 2013;5:85\u201397. https:\/\/doi.org\/10.2147\/CPAA.S42796.","journal-title":"Clin Pharmacol"},{"key":"1684_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/BJH.17654","volume":"194","author":"P Rousselot","year":"2021","unstructured":"Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021;194:393\u2013402. https:\/\/doi.org\/10.1111\/BJH.17654.","journal-title":"Br J Haematol"},{"key":"1684_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/S00280-012-1998-4","volume":"71","author":"PH Hsyu","year":"2013","unstructured":"Hsyu PH, Mould DR, Upton RN, Amantea M. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2013;71:209\u201318. https:\/\/doi.org\/10.1007\/S00280-012-1998-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1684_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/S40164-018-0101-1","volume":"7","author":"A Mita","year":"2018","unstructured":"Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, et al. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018;7:9. https:\/\/doi.org\/10.1186\/S40164-018-0101-1.","journal-title":"Exp Hematol Oncol"},{"key":"1684_CR37","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255\/274400\/AM\/INDIVIDUALIZED-PAZOPANIB-DOSING-A-PROSPECTIVE","volume":"22","author":"RB Verheijen","year":"2016","unstructured":"Verheijen RB, Bins S, Mathijssen RHJ, Lolkema MP, Van Doorn L, Schellens JHM, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016;22:5738\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1255\/274400\/AM\/INDIVIDUALIZED-PAZOPANIB-DOSING-A-PROSPECTIVE.","journal-title":"Clin Cancer Res"},{"key":"1684_CR38","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","volume":"22","author":"MS Marcolino","year":"2011","unstructured":"Marcolino MS, Boersma E, Clementino NCD, Macedo AV, Marx-Neto AD, Silva MHCR, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22:2073\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdq715.","journal-title":"Ann Oncol"},{"key":"1684_CR39","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/CNCR.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, Nogueras-Gonz\u00e1lez GM, Burger J, Ferrajoli A, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121:3894\u2013904. https:\/\/doi.org\/10.1002\/CNCR.29587.","journal-title":"Cancer"},{"key":"1684_CR40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/NEP.14014","volume":"27","author":"AK Singh","year":"2022","unstructured":"Singh AK, Hussain S, Ahmed R, Agrawal N, Bhurani D, Klugar M, et al. Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients. Nephrology. 2022;27:318\u201326. https:\/\/doi.org\/10.1111\/NEP.14014.","journal-title":"Nephrology"},{"key":"1684_CR41","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/CNCR.34478","volume":"128","author":"F Cheng","year":"2022","unstructured":"Cheng F, Zeng F, Li Q, Cui Z, Chen Y, Li W, et al. Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia. Cancer. 2022;128:3951\u20138. https:\/\/doi.org\/10.1002\/CNCR.34478.","journal-title":"Cancer"},{"key":"1684_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/S00280-023-04581-0","volume":"92","author":"S He","year":"2023","unstructured":"He S, Shao Q, Zhao J, Bian J, Zhao Y, Hao X, et al. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation. Cancer Chemother Pharmacol. 2023;92:399\u2013410. https:\/\/doi.org\/10.1007\/S00280-023-04581-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1684_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/00498254.2016.1179821","volume":"47","author":"PN Morcos","year":"2017","unstructured":"Morcos PN, Yu L, Bogman K, Sato M, Katsuki H, Kawashima K, et al. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica. 2017;47:217\u201329. https:\/\/doi.org\/10.1080\/00498254.2016.1179821.","journal-title":"Xenobiotica"},{"key":"1684_CR44","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1634\/THEONCOLOGIST.2009-0088","volume":"14","author":"A Kim","year":"2009","unstructured":"Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist. 2009;14:800. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2009-0088.","journal-title":"Oncologist"},{"key":"1684_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/0091270009347868;PAGEGROUP:STRING:PUBLICATION","volume":"50","author":"R Khosravan","year":"2010","unstructured":"Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol. 2010;50:472\u201381. https:\/\/doi.org\/10.1177\/0091270009347868;PAGEGROUP:STRING:PUBLICATION.","journal-title":"J Clin Pharmacol"},{"key":"1684_CR46","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/J.1464-410X.2010.09990.X","volume":"108","author":"D Josephs","year":"2011","unstructured":"Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 2011;108:1279\u201383. https:\/\/doi.org\/10.1111\/J.1464-410X.2010.09990.X.","journal-title":"BJU Int"},{"key":"1684_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3904\/KJIM.2014.29.1.40","volume":"29","author":"SH Baek","year":"2014","unstructured":"Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med. 2014;29:40. https:\/\/doi.org\/10.3904\/KJIM.2014.29.1.40.","journal-title":"Korean J Intern Med"},{"key":"1684_CR48","doi-asserted-by":"publisher","first-page":"e13726","DOI":"10.1097\/MD.0000000000013726","volume":"98","author":"J Li","year":"2019","unstructured":"Li J, Yuan Z, Wang Q, Fan W, Zhang G. Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer. Medicine. 2019;98:e13726. https:\/\/doi.org\/10.1097\/MD.0000000000013726.","journal-title":"Medicine"},{"key":"1684_CR49","unstructured":"Imatinib. LiverTox: clinical and research information on drug-induced liver injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547959\/. Accessed 22 Jan 2025."},{"key":"1684_CR50","doi-asserted-by":"publisher","unstructured":"Aleksandrovich Y, Bassett J, Melquist S, Estepp K, Hamedani FS, Wiisanen J, et al. S2660 imatinib mesylate (gleevec)-induced acute liver failure successfully treated with prednisolone Therapy. Am J Gastroenterol; 2020;115:1394. https:\/\/doi.org\/10.14309\/01.AJG.0000712688.47583.F8.","DOI":"10.14309\/01.AJG.0000712688.47583.F8"},{"key":"1684_CR51","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ANNONC\/MDY019","volume":"29","author":"HJ Khoury","year":"2018","unstructured":"Khoury HJ, Gambacorti-Passerini C, Br\u00fcmmendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018;29:578. https:\/\/doi.org\/10.1093\/ANNONC\/MDY019.","journal-title":"Ann Oncol"},{"key":"1684_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/S00228-011-1200-7","volume":"68","author":"RA Larson","year":"2011","unstructured":"Larson RA, Yin OQP, Hochhaus A, Saglio G, Clark RE, Nakamae H, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2011;68:723. https:\/\/doi.org\/10.1007\/S00228-011-1200-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"1684_CR53","doi-asserted-by":"publisher","unstructured":"Yoo C, Ryu M-H, Ryoo B-Y, Youl Beck M, Chang H-M, Lee J-L, et al. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. https:\/\/doi.org\/10.1007\/s10637-011-9633-5.","DOI":"10.1007\/s10637-011-9633-5"},{"key":"1684_CR54","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008;14:7102\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0950.","journal-title":"Clin Cancer Res"},{"key":"1684_CR55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/J.CTRV.2010.10.001","volume":"37","author":"M Von Mehren","year":"2010","unstructured":"Von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing. Cancer Treat Rev. 2010;37:291. https:\/\/doi.org\/10.1016\/J.CTRV.2010.10.001.","journal-title":"Cancer Treat Rev"},{"key":"1684_CR56","doi-asserted-by":"publisher","unstructured":"Ae IJ, Ma P, Bin AE, Ae P, Verweij J, Ae AR, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. https:\/\/doi.org\/10.1007\/s00280-004-0876-0.","DOI":"10.1007\/s00280-004-0876-0"},{"key":"1684_CR57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4274\/TJH.2014.0213","volume":"33","author":"OM Akay","year":"2016","unstructured":"Akay OM, Mutlu F, G\u00fclba\u015f Z. Platelet dysfunction in patients with chronic myeloid leukemia: does imatinib mesylate improve it? Turk J Haematol. 2016;33:127\u201330. https:\/\/doi.org\/10.4274\/TJH.2014.0213.","journal-title":"Turk J Haematol"},{"key":"1684_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1182\/BLOOD-2008-09-180604","volume":"114","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor\u2013induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261\u20133. https:\/\/doi.org\/10.1182\/BLOOD-2008-09-180604.","journal-title":"Blood"},{"key":"1684_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00280-022-04454-y","volume":"90","author":"Y-H Chien","year":"2022","unstructured":"Chien Y-H, W\u00fcrthwein G, Zubiaur P, Posocco B, Mar\u00eda P\u00c1, et al. Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg. Cancer Chemother Pharmacol. 2022;90:125\u201336. https:\/\/doi.org\/10.1007\/s00280-022-04454-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1684_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/J.1365-2125.2006.02719.X","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97\u2013112. https:\/\/doi.org\/10.1111\/J.1365-2125.2006.02719.X.","journal-title":"Br J Clin Pharmacol"},{"key":"1684_CR61","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","volume":"12","author":"C Delbaldo","year":"2006","unstructured":"Delbaldo C, Chatelut E, R\u00e9 M, Deroussent A, S\u00e9ronie-Vivien S, Jambu A, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12:6073\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2596.","journal-title":"Clin Cancer Res"},{"key":"1684_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14010119","author":"A Telerman","year":"2021","unstructured":"Telerman A, Granot G, Leibovitch C, Yarchovsky-Dolberg O, Shacham-Abulafia A, Partouche S, et al. Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differentially affected by tyrosine kinase inhibitors. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/CANCERS14010119.","journal-title":"Cancers (Basel)"},{"key":"1684_CR63","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/J.CLINTHERA.2011.04.005","volume":"33","author":"L Zhang","year":"2011","unstructured":"Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011;33:315\u201327. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2011.04.005.","journal-title":"Clin Ther"},{"key":"1684_CR64","doi-asserted-by":"publisher","unstructured":"Houk BE, Bello CL, Poland B, Lee, Rosen S, Demetri GD, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. https:\/\/doi.org\/10.1007\/s00280-009-1170-y.","DOI":"10.1007\/s00280-009-1170-y"},{"key":"1684_CR65","doi-asserted-by":"publisher","first-page":"1398055","DOI":"10.3389\/FONC.2024.1398055","volume":"14","author":"E Fassi","year":"2014","unstructured":"Fassi E, Amoroso V, Cosentini D, Ferrari V, Lagan\u00e0 M, Berruti A, et al. Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report. Front Oncol. 2014;14:1398055. https:\/\/doi.org\/10.3389\/FONC.2024.1398055.","journal-title":"Front Oncol"},{"key":"1684_CR66","doi-asserted-by":"publisher","first-page":"104002","DOI":"10.1016\/J.ESMOOP.2024.104002","volume":"9","author":"J Delahousse","year":"2024","unstructured":"Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F, et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 2024;9:104002. https:\/\/doi.org\/10.1016\/J.ESMOOP.2024.104002.","journal-title":"ESMO Open"},{"key":"1684_CR67","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/S10147-018-1300-9","volume":"23","author":"S Mizuta","year":"2018","unstructured":"Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, et al. Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018;23:980. https:\/\/doi.org\/10.1007\/S10147-018-1300-9.","journal-title":"Int J Clin Oncol"},{"key":"1684_CR68","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/S00280-018-3597-5","volume":"82","author":"PN Morcos","year":"2018","unstructured":"Morcos PN, Nueesch E, Jaminion F, Guerini E, Hsu JC, Bordogna W, et al. Exposure\u2013response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2018;82:129. https:\/\/doi.org\/10.1007\/S00280-018-3597-5.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1684_CR69","doi-asserted-by":"publisher","first-page":"e20575","DOI":"10.1200\/JCO.2019.37.15_SUPPL.E20575","volume":"37","author":"K Smart","year":"2019","unstructured":"Smart K, Hsu JC, Jaminion F, Guerini E, Shaw AT, Zhou C, et al. Alectinib exposure-response (ER) in ALK-inhibitor na\u00efve ALK-positive NSCLC patients: pooled analysis across phase III studies. J Clin Oncol. 2019;37:e20575\u2013e20575. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_SUPPL.E20575.","journal-title":"J Clin Oncol"},{"key":"1684_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-23","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Scott SA, Niioka T, Sawada K. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. J Hematol Oncol. 2012. https:\/\/doi.org\/10.1186\/1756-8722-5-23.","journal-title":"J Hematol Oncol"},{"key":"1684_CR71","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/BPB.B15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38:645\u201354. https:\/\/doi.org\/10.1248\/BPB.B15-00103.","journal-title":"Biol Pharm Bull"},{"key":"1684_CR72","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1200\/JCO.2008.26.15_SUPPL.3590","volume":"26","author":"X Wang","year":"2008","unstructured":"Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol. 2008;26:3590\u20133590. https:\/\/doi.org\/10.1200\/JCO.2008.26.15_SUPPL.3590.","journal-title":"J Clin Oncol"},{"key":"1684_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/S12032-019-1263-3","author":"M Nagahama","year":"2019","unstructured":"Nagahama M, Ozeki T, Suzuki A, Sugino K, Niioka T, Ito K, et al. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol. 2019. https:\/\/doi.org\/10.1007\/S12032-019-1263-3.","journal-title":"Med Oncol"},{"key":"1684_CR74","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/JCPH.917","volume":"57","author":"T Tamai","year":"2017","unstructured":"Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017;57:1138\u201347. https:\/\/doi.org\/10.1002\/JCPH.917.","journal-title":"J Clin Pharmacol"},{"key":"1684_CR75","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/S00280-018-3687-4\/FIGURES\/3","volume":"82","author":"S Hayato","year":"2018","unstructured":"Hayato S, Shumaker R, Ferry J, Binder T, Dutcus CE, Hussein Z. Exposure\u2013response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemother Pharmacol. 2018;82:971\u20138. https:\/\/doi.org\/10.1007\/S00280-018-3687-4\/FIGURES\/3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1684_CR76","unstructured":"FDA. Center for drug evaluation and research application number: 206947orig1s000 clinical pharmacology and biopharmaceutics review(S) [Internet]. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206947orig1s000clinpharmr.pdf. Accessed 28 Nov 2024."},{"key":"1684_CR77","doi-asserted-by":"publisher","first-page":"22811","DOI":"10.3390\/IJMS160922811","volume":"16","author":"M Polillo","year":"2015","unstructured":"Polillo M, Galimberti S, Barat\u00e8 C, Petrini M, Danesi R, Di Paolo A. Pharmacogenetics of BCR\/ABL inhibitors in chronic myeloid leukemia. Int J Mol Sci. 2015;16:22811. https:\/\/doi.org\/10.3390\/IJMS160922811.","journal-title":"Int J Mol Sci"},{"key":"1684_CR78","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1007\/S10637-021-01115-4\/FIGURES\/5","volume":"39","author":"M Fukudo","year":"2021","unstructured":"Fukudo M, Asai K, Tani C, Miyamoto M, Ando K, Ueno N. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. Investig New Drugs. 2021;39:1422\u201331. https:\/\/doi.org\/10.1007\/S10637-021-01115-4\/FIGURES\/5.","journal-title":"Investig New Drugs"},{"key":"1684_CR79","unstructured":"FDA. Center For drug evaluation and research application number: 203085Orig1s000 clinical pharmacology and biopharmaceutics review(S [Internet]. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203085Orig1s000ClinPharmR.pdf. Accessed 28 Nov 2024."},{"key":"1684_CR80","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/J.EJPS.2017.05.050","volume":"109S","author":"A Solms","year":"2017","unstructured":"Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, Bruix J, et al. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. Eur J Pharm Sci. 2017;109S:S149\u201353. https:\/\/doi.org\/10.1016\/J.EJPS.2017.05.050.","journal-title":"Eur J Pharm Sci"},{"key":"1684_CR81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.CLCC.2019.10.004","volume":"19","author":"T Suzuki","year":"2020","unstructured":"Suzuki T, Sukawa Y, Imamura CK, Masuishi T, Satake H, Kumekawa Y, et al. A phase II study of regorafenib with a lower starting dose in patients with metastatic colorectal cancer: exposure-toxicity analysis of unbound regorafenib and its active metabolites (RESET Trial). Clin Colorectal Cancer. 2020;19:13-21.e3. https:\/\/doi.org\/10.1016\/J.CLCC.2019.10.004.","journal-title":"Clin Colorectal Cancer"},{"key":"1684_CR82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.2011.29.7_SUPPL.345","volume":"29","author":"Y Lin","year":"2011","unstructured":"Lin Y, Ball HA, Suttle B, Mehmud F, Amado RG, Hutson TE, et al. Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma. J Clin Oncol. 2011;29:345\u2013345. https:\/\/doi.org\/10.1200\/JCO.2011.29.7_SUPPL.345.","journal-title":"J Clin Oncol"},{"key":"1684_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/FTD.0000000000000141","volume":"37","author":"D De Wit","year":"2015","unstructured":"De Wit D, Van Erp NP, Den Hartigh J, Wolterbeek R, Den Hollander-Van Deursen M, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37:331\u20138. https:\/\/doi.org\/10.1097\/FTD.0000000000000141.","journal-title":"Ther Drug Monit"},{"key":"1684_CR84","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/S40262-016-0443-Y\/FIGURES\/6","volume":"56","author":"H Yu","year":"2017","unstructured":"Yu H, van Erp N, Bins S, Mathijssen RHJ, Schellens JHM, Beijnen JH, et al. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet. 2017;56:293\u2013303. https:\/\/doi.org\/10.1007\/S40262-016-0443-Y\/FIGURES\/6.","journal-title":"Clin Pharmacokinet"},{"key":"1684_CR85","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/BJC.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909\u201316. https:\/\/doi.org\/10.1038\/BJC.2014.503.","journal-title":"Br J Cancer"},{"key":"1684_CR86","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","volume":"24","author":"CN Sternberg","year":"2018","unstructured":"Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, et al. Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Res. 2018;24:3005\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2652.","journal-title":"Clin Cancer Res"},{"key":"1684_CR87","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/S00280-017-3463-X\/FIGURES\/4","volume":"80","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol. 2017;80:1171\u20138. https:\/\/doi.org\/10.1007\/S00280-017-3463-X\/FIGURES\/4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1684_CR88","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/J.CLGC.2018.12.001","volume":"17","author":"S Noda","year":"2019","unstructured":"Noda S, Yoshida T, Hira D, Murai R, Tomita K, Tsuru T, et al. Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. Clin Genitourin Cancer. 2019;17:e306\u201313. https:\/\/doi.org\/10.1016\/J.CLGC.2018.12.001.","journal-title":"Clin Genitourin Cancer"},{"key":"1684_CR89","unstructured":"FDA. Center for drug evaluation and research application number: 22-465 clinical pharmacology and biopharmaceutics review [Internet]. 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_clinpharmr.pdf. Accessed 28 Nov 2024."},{"key":"1684_CR90","unstructured":"FDA. Center for drug evaluation and research application number: 203469orig1s000 clinical pharmacology and biopharmaceutics review(s [Internet]. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205832Orig1s000ClinPharmR.pdf. Accessed 28 Nov 2024."},{"key":"1684_CR91","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/J.LEUKRES.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391. https:\/\/doi.org\/10.1016\/J.LEUKRES.2016.07.007.","journal-title":"Leuk Res"},{"key":"1684_CR92","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/S10147-018-1302-7","volume":"23","author":"S Takasaki","year":"2018","unstructured":"Takasaki S, Kawasaki Y, Kikuchi M, Tanaka M, Suzuka M, Noda A, et al. Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol. 2018;23:936\u201343. https:\/\/doi.org\/10.1007\/S10147-018-1302-7.","journal-title":"Int J Clin Oncol"},{"key":"1684_CR93","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.CLGC.2015.01.007","volume":"13","author":"S Noda","year":"2015","unstructured":"Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, et al. Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer. 2015;13:350\u20138. https:\/\/doi.org\/10.1016\/J.CLGC.2015.01.007.","journal-title":"Clin Genitourin Cancer"},{"key":"1684_CR94","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221085212","author":"T Chen","year":"2022","unstructured":"Chen T, Chen J, Chen C, Guo J, He X, Zheng S, et al. Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma. Ther Adv Med Oncol. 2022. https:\/\/doi.org\/10.1177\/17588359221085212.","journal-title":"Ther Adv Med Oncol"},{"key":"1684_CR95","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1038\/BJC.2014.194","volume":"110","author":"NAG Lankheet","year":"2014","unstructured":"Lankheet NAG, Kloth JSL, Gadellaa-Van Hooijdonk CGM, Cirkel GA, Mathijssen RHJ, Lolkema MPJK, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110:2441\u20139. https:\/\/doi.org\/10.1038\/BJC.2014.194.","journal-title":"Br J Cancer"},{"key":"1684_CR96","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25\u201335. https:\/\/doi.org\/10.1200\/JCO.2005.02.2194.","journal-title":"J Clin Oncol"},{"key":"1684_CR97","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/S00280-016-2993-Y","volume":"77","author":"D Ouellet","year":"2016","unstructured":"Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, et al. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol. 2016;77:807\u201317. https:\/\/doi.org\/10.1007\/S00280-016-2993-Y.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01684-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:59:23Z","timestamp":1788530363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":97,"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01684-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was waived by the University of Groningen Medical Centre (UMCG) Medical Ethics Committee (METc 2024\/152).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No code was generated or used for this study.","order":4,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daan J. Touw is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. BG, ZAS, PM, AD, AJW, EB, SKK, TOM, and MdH have no conflict of interest to declare.","order":5,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was waived by the University of Groningen Medical Centre (UMCG) Medical Ethics Committee (METc 2024\/152).","order":6,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}